Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 8/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 3/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16623680 | 0.87 | GPR84 (0.36) | GPR84NPBWR1GRM2DHFR | |
| SCHEMBL9104746 | 0.85 | PLA2G7 (0.51) | PLA2G7RAF1BRAFGPR84 | |
| SCHEMBL16623946 | 0.81 | PLA2G7 (0.42) | PLA2G7RAF1BRAFNR1H2NR1H3 | |
| SCHEMBL9107928 | 0.80 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL9108664 | 0.80 | PLA2G7 (0.53) | PLA2G7GPR84 | |
| SCHEMBL9103226 | 0.78 | PLA2G7 (0.49) | PLA2G7RAF1BRAFGPR84 | |
| SCHEMBL9107505 | 0.77 | GPR84 (0.39) | PLA2G7GPR84 | |
| SCHEMBL9109328 | 0.77 | PLA2G7 (0.35) | PLA2G7BRAFGPR84NPBWR1 | |
| SCHEMBL9103260 | 0.76 | PLA2G7 (0.51) | PLA2G7RAF1BRAFGPR84 | |
| SCHEMBL9101676 | 0.75 | PLA2G7 (0.63) | PLA2G7RAF1BRAFGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | PLA2G7 4/4885RAF1 2923/4885BRAF 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.